Security key
697947109
PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA)
CUSIP: 697947109
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.01 par value
- Total 13F shares
- 100
- Total 13F value
- $15,282
- Share change
- +72
- SEC-reported price per share
- $152.82
- Number of holders
- 3
- Value change
- +$11,003
- Number of buys
- 3
- Shares outstanding
- 11,842,870
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
PVLA full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
PALVELLA THERAPEUTICS, INC. SEC filings
PALVELLA THERAPEUTICS, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 697947109
Recent filing periods:
Ownership snapshot
Top reported holders of PVLA - PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Kaupinen Wes
Disclosed value leader
SUVRETTA CAPITAL MANAGEME...
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 15%
13D/G row: Kaupinen Wes
Showing 1-6 of 15 holder rows.
Quick read
Kaupinen Wes leads the comparable SEC ownership view at 15%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Kaupinen Wes's linked filing trail.
Comparable ownership
Top 5
Kaupinen Wes
15%
First Light Asset Management, LLC
7.5%
SUVRETTA CAPITAL MANAGEMENT, LLC
7.4%
BIOTECHNOLOGY VALUE FUND L P
7.1%
Frazier Life Sciences Public Fund...
6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Kaupinen Wes |
13D/G
3/4/5
President and CEO, Director, 10%+ Owner
|
15%
|
$38,555,729
1,644,869 shares
|
$0 | 13 Dec 2024 |
| First Light Asset Management, LLC |
13F
13D/G
Company
|
7.5%
from 13D/G
|
$122,251,485
980,758 shares
|
— | 31 Mar 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
13D/G
Company
|
7.4%
from 13D/G
|
$143,783,276
1,153,496 shares
|
— | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
7.1%
|
$88,331,614
879,009 shares
|
-$30,366,571 | 31 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
6%
|
$70,982,116
706,360 shares
|
+$16,164,419 | 31 Dec 2025 |
| Samsara BioCapital, L.P. |
13D/G
|
3.1%
|
$8,989,600
339,743 shares
|
-$8,989,600 | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
100
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
178
Q2 2026 holders
3
Holder diff
-175
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend